|Bid||25.00 x 1000|
|Ask||27.00 x 1000|
|Day's Range||25.52 - 26.99|
|52 Week Range||9.24 - 30.13|
|Beta (5Y Monthly)||1.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
Myriad Genetics stock traded higher after the diagnostic-testing company said it was pursuing strategic alternatives for its Vectra autoimmune business.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.